✦ LIBER ✦

604 Pegylated interfon for treatment of acute hepatitis C in Egypt (ANRS 1213 trial)

Book ID: 117374110
Publisher: Elsevier Science
Year: 2005
Tongue: English
Weight: 127 KB
Volume: 42
Category: Article
ISSN: 0168-8278
DOI: 10.1016/s0168-8278(05)82015-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

P.244 Pegylated interferon alpha-2a for

P.244 Pegylated interferon alpha-2a for treatment of acute hepatitis C in Egypt (ANRS 1213 trial)

✍ S.A. Ismail; M.K. Mohamed; H. Mansour; C. Rekacewicz; R.R. Gad; M. El-Houssinie; 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 145 KB

559 Combined pegylated interferon α-2a a

559 Combined pegylated interferon α-2a and ribavirin in treatment of chronic hepatitis C in Egypt (ANRS 1211 Trial)

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 126 KB

P.247 Prediction of treatment outcome in

P.247 Prediction of treatment outcome in genotype 4 chronic hepatitis C patients during combined pegylated interferon alpha-2a and ribavirin therapy (ANRS 1211 trial)

✍ G. Esmat; H. ElMakhzangy; S. Males; R.R. Gad; C. Rekacewicz; S.A. Ismail; M. Abd 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 143 KB

Telaprevir for HIV/Hepatitis C Virus-Coi

Telaprevir for HIV/Hepatitis C Virus-Coinfected Patients Failing Treatment With Pegylated Interferon/Ribavirin (ANRS HC26 TelapreVIH): An Open-Label, Single-Arm, Phase 2 Trial

✍ Cotte, L.; Braun, J.; Lascoux-Combe, C.; Vincent, C.; Valantin, M.-A.; Sogni, P. 📂 Article 📅 2014 🏛 University of Chicago Press 🌐 English ⚖ 525 KB

Variants in interferon-alpha pathway gen

Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial

✍ Tania Mara Welzel; Timothy R. Morgan; Herbert L. Bonkovsky; Deepa Naishadham; Ru 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 270 KB 👁 2 views

Combination treatment with pegylated-interferon-alpha (PEG IFN-␣) and ribavirin, the current recommended therapy for chronic hepatitis C virus (HCV) infection, results in a sustained virological response (SVR) in only about half of patients. Because genes involved in the interferon-alpha pathway may

Boceprevir versus placebo with pegylated

Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial

✍ Sulkowski, Mark; Pol, Stanislas; Mallolas, Josep; Fainboim, Hugo; Cooper, Curtis 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 333 KB